Fingolimod-associated PML with mild IRIS in MS: A clinicopathologic study.

Journal: Neurology(R) neuroimmunology & neuroinflammation
Published Date:

Abstract

OBJECTIVE: To clarify the clinical, neuropathologic, and virologic characteristics of progressive multifocal leukoencephalopathy (PML) and its immune reconstitution inflammatory syndrome (IRIS) in a patient with fingolimod-treated MS.

Authors

  • Shuhei Nishiyama
    Department of Neurology (S.N., T.M., Y.T., K.T., N.Y., H.K., M.A.), Department of Multiple Sclerosis Therapeutics (T.M.), Department of Neurosurgery (R.S., T.T.), and Department of Pathology (M.W.), Tohoku University Graduate School of Medicine, Sendai; Department of Anatomic Pathology (Y.S.-H.), Tokyo Medical University; Department of Virology 1 (K.N., M.S.), Laboratory of Neurovirology, National Institute of Infectious Diseases; Department of Neurology (I.N.), Tohoku Medical and Pharmaceutical University, Sendai; and Department of Multiple Sclerosis Therapeutics (K.F.), Fukushima Medical University School of Medicine and Multiple Sclerosis and Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, Japan.
  • Tatsuro Misu
    Department of Neurology (S.N., T.M., Y.T., K.T., N.Y., H.K., M.A.), Department of Multiple Sclerosis Therapeutics (T.M.), Department of Neurosurgery (R.S., T.T.), and Department of Pathology (M.W.), Tohoku University Graduate School of Medicine, Sendai; Department of Anatomic Pathology (Y.S.-H.), Tokyo Medical University; Department of Virology 1 (K.N., M.S.), Laboratory of Neurovirology, National Institute of Infectious Diseases; Department of Neurology (I.N.), Tohoku Medical and Pharmaceutical University, Sendai; and Department of Multiple Sclerosis Therapeutics (K.F.), Fukushima Medical University School of Medicine and Multiple Sclerosis and Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, Japan.
  • Yukiko Shishido-Hara
    Department of Neurology (S.N., T.M., Y.T., K.T., N.Y., H.K., M.A.), Department of Multiple Sclerosis Therapeutics (T.M.), Department of Neurosurgery (R.S., T.T.), and Department of Pathology (M.W.), Tohoku University Graduate School of Medicine, Sendai; Department of Anatomic Pathology (Y.S.-H.), Tokyo Medical University; Department of Virology 1 (K.N., M.S.), Laboratory of Neurovirology, National Institute of Infectious Diseases; Department of Neurology (I.N.), Tohoku Medical and Pharmaceutical University, Sendai; and Department of Multiple Sclerosis Therapeutics (K.F.), Fukushima Medical University School of Medicine and Multiple Sclerosis and Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, Japan.
  • Kazuo Nakamichi
    Department of Neurology (S.N., T.M., Y.T., K.T., N.Y., H.K., M.A.), Department of Multiple Sclerosis Therapeutics (T.M.), Department of Neurosurgery (R.S., T.T.), and Department of Pathology (M.W.), Tohoku University Graduate School of Medicine, Sendai; Department of Anatomic Pathology (Y.S.-H.), Tokyo Medical University; Department of Virology 1 (K.N., M.S.), Laboratory of Neurovirology, National Institute of Infectious Diseases; Department of Neurology (I.N.), Tohoku Medical and Pharmaceutical University, Sendai; and Department of Multiple Sclerosis Therapeutics (K.F.), Fukushima Medical University School of Medicine and Multiple Sclerosis and Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, Japan.
  • Masayuki Saijo
    Department of Neurology (S.N., T.M., Y.T., K.T., N.Y., H.K., M.A.), Department of Multiple Sclerosis Therapeutics (T.M.), Department of Neurosurgery (R.S., T.T.), and Department of Pathology (M.W.), Tohoku University Graduate School of Medicine, Sendai; Department of Anatomic Pathology (Y.S.-H.), Tokyo Medical University; Department of Virology 1 (K.N., M.S.), Laboratory of Neurovirology, National Institute of Infectious Diseases; Department of Neurology (I.N.), Tohoku Medical and Pharmaceutical University, Sendai; and Department of Multiple Sclerosis Therapeutics (K.F.), Fukushima Medical University School of Medicine and Multiple Sclerosis and Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, Japan.
  • Yoshiki Takai
    Department of Neurology (S.N., T.M., Y.T., K.T., N.Y., H.K., M.A.), Department of Multiple Sclerosis Therapeutics (T.M.), Department of Neurosurgery (R.S., T.T.), and Department of Pathology (M.W.), Tohoku University Graduate School of Medicine, Sendai; Department of Anatomic Pathology (Y.S.-H.), Tokyo Medical University; Department of Virology 1 (K.N., M.S.), Laboratory of Neurovirology, National Institute of Infectious Diseases; Department of Neurology (I.N.), Tohoku Medical and Pharmaceutical University, Sendai; and Department of Multiple Sclerosis Therapeutics (K.F.), Fukushima Medical University School of Medicine and Multiple Sclerosis and Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, Japan.
  • Kentarou Takei
    Department of Neurology (S.N., T.M., Y.T., K.T., N.Y., H.K., M.A.), Department of Multiple Sclerosis Therapeutics (T.M.), Department of Neurosurgery (R.S., T.T.), and Department of Pathology (M.W.), Tohoku University Graduate School of Medicine, Sendai; Department of Anatomic Pathology (Y.S.-H.), Tokyo Medical University; Department of Virology 1 (K.N., M.S.), Laboratory of Neurovirology, National Institute of Infectious Diseases; Department of Neurology (I.N.), Tohoku Medical and Pharmaceutical University, Sendai; and Department of Multiple Sclerosis Therapeutics (K.F.), Fukushima Medical University School of Medicine and Multiple Sclerosis and Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, Japan.
  • Naoki Yamamoto
    Department of Neuropsychiatry, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan.
  • Hiroshi Kuroda
    Department of Neurology (S.N., T.M., Y.T., K.T., N.Y., H.K., M.A.), Department of Multiple Sclerosis Therapeutics (T.M.), Department of Neurosurgery (R.S., T.T.), and Department of Pathology (M.W.), Tohoku University Graduate School of Medicine, Sendai; Department of Anatomic Pathology (Y.S.-H.), Tokyo Medical University; Department of Virology 1 (K.N., M.S.), Laboratory of Neurovirology, National Institute of Infectious Diseases; Department of Neurology (I.N.), Tohoku Medical and Pharmaceutical University, Sendai; and Department of Multiple Sclerosis Therapeutics (K.F.), Fukushima Medical University School of Medicine and Multiple Sclerosis and Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, Japan.
  • Ryuta Saito
    Department of Neurology (S.N., T.M., Y.T., K.T., N.Y., H.K., M.A.), Department of Multiple Sclerosis Therapeutics (T.M.), Department of Neurosurgery (R.S., T.T.), and Department of Pathology (M.W.), Tohoku University Graduate School of Medicine, Sendai; Department of Anatomic Pathology (Y.S.-H.), Tokyo Medical University; Department of Virology 1 (K.N., M.S.), Laboratory of Neurovirology, National Institute of Infectious Diseases; Department of Neurology (I.N.), Tohoku Medical and Pharmaceutical University, Sendai; and Department of Multiple Sclerosis Therapeutics (K.F.), Fukushima Medical University School of Medicine and Multiple Sclerosis and Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, Japan.
  • Mika Watanabe
    Department of Neurology (S.N., T.M., Y.T., K.T., N.Y., H.K., M.A.), Department of Multiple Sclerosis Therapeutics (T.M.), Department of Neurosurgery (R.S., T.T.), and Department of Pathology (M.W.), Tohoku University Graduate School of Medicine, Sendai; Department of Anatomic Pathology (Y.S.-H.), Tokyo Medical University; Department of Virology 1 (K.N., M.S.), Laboratory of Neurovirology, National Institute of Infectious Diseases; Department of Neurology (I.N.), Tohoku Medical and Pharmaceutical University, Sendai; and Department of Multiple Sclerosis Therapeutics (K.F.), Fukushima Medical University School of Medicine and Multiple Sclerosis and Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, Japan.
  • Teiji Tominaga
    Department of Neurosurgery, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
  • Ichiro Nakashima
    Department of Neurology (S.N., T.M., Y.T., K.T., N.Y., H.K., M.A.), Department of Multiple Sclerosis Therapeutics (T.M.), Department of Neurosurgery (R.S., T.T.), and Department of Pathology (M.W.), Tohoku University Graduate School of Medicine, Sendai; Department of Anatomic Pathology (Y.S.-H.), Tokyo Medical University; Department of Virology 1 (K.N., M.S.), Laboratory of Neurovirology, National Institute of Infectious Diseases; Department of Neurology (I.N.), Tohoku Medical and Pharmaceutical University, Sendai; and Department of Multiple Sclerosis Therapeutics (K.F.), Fukushima Medical University School of Medicine and Multiple Sclerosis and Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, Japan.
  • Kazuo Fujihara
    Department of Neurology (S.N., T.M., Y.T., K.T., N.Y., H.K., M.A.), Department of Multiple Sclerosis Therapeutics (T.M.), Department of Neurosurgery (R.S., T.T.), and Department of Pathology (M.W.), Tohoku University Graduate School of Medicine, Sendai; Department of Anatomic Pathology (Y.S.-H.), Tokyo Medical University; Department of Virology 1 (K.N., M.S.), Laboratory of Neurovirology, National Institute of Infectious Diseases; Department of Neurology (I.N.), Tohoku Medical and Pharmaceutical University, Sendai; and Department of Multiple Sclerosis Therapeutics (K.F.), Fukushima Medical University School of Medicine and Multiple Sclerosis and Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, Japan.
  • Masashi Aoki
    Department of Neurology (S.N., T.M., Y.T., K.T., N.Y., H.K., M.A.), Department of Multiple Sclerosis Therapeutics (T.M.), Department of Neurosurgery (R.S., T.T.), and Department of Pathology (M.W.), Tohoku University Graduate School of Medicine, Sendai; Department of Anatomic Pathology (Y.S.-H.), Tokyo Medical University; Department of Virology 1 (K.N., M.S.), Laboratory of Neurovirology, National Institute of Infectious Diseases; Department of Neurology (I.N.), Tohoku Medical and Pharmaceutical University, Sendai; and Department of Multiple Sclerosis Therapeutics (K.F.), Fukushima Medical University School of Medicine and Multiple Sclerosis and Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, Japan.

Keywords

No keywords available for this article.